Fusion Pharmaceuticals has nominated the first targeted alpha therapy (TAT) candidate under its partnership agreement with AstraZeneca to commence Phase I clinical trials.

The companies will co-develop the new TAT through a Phase I trial.

The new TAT leverages the Fast-Clear linker technology of Fusion to radiolabel an AstraZeneca-owned bispecific antibody with actinium-225 alpha-emitting isotope.

According to the prior partnership agreement, Fusion will handle the preclinical development through first-in-human trials while AstraZeneca will oversee the following clinical development. 

Fusion and AstraZeneca will split clinical development expenditures equally, with investigational new drug (IND)-enabling studies underway.

Fusion Pharmaceuticals CEO John Valliant said: “Fusion is at the forefront developing a new wave of cancer therapies using alpha-emitting medical isotopes and various targeting vehicles. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“One of the pillars of our platform is to create next-generation immunoconjugates, and we are excited to be working with AstraZeneca to pursue a novel radioimmunoconjugate for oncology. 

“We had strong alignment among our joint development committee to move this novel TAT forward into a planned Phase I study and we look forward to sharing more information as we approach the investigational new drug application (IND) filing.”

Fusion and AstraZeneca currently have a partnership for the co-development of up to three new TATs.

Up to five combination programmes would also be explored between TATs of Fusion and AstraZeneca’s DNA damage response inhibitors and immuno-oncology agents.

A lead programme of Fusion, FPI-1434 acts on the insulin-like growth factor 1 receptor and is presently being analysed in a Phase I trial. 

The company’s pipeline comprises FPI-1966 and FPI-2059, the latter being a small molecule acquired by Fusion from Ipsen.

Last December, AstraZeneca and Ionis Pharmaceuticals entered an agreement for the development and commercialisation of eplontersen.